AR and COVID-19: Drugs that target androgen receptor (AR) signaling, including those that inhibit production of androgen ligands (degarelix) and those that bind to and directly block AR activity (enzalutamide), have been investigated in clinical trials for the treatment of COVID-19 but failed to produce positive results.